Shots:

• The company reported the commercial availability of Genolar biosimilar of omalizumab in Russia for persistent atopic bronchial asthma & resistant chronic idiopathic urticaria & marks the 3rd biosimilar under the commercial license agreements b/w selexis & generium
• It marks the 9th marketed biologic product & will use Selexis’ SUREtechnology platform which has builts from Selexis SGE that control the dynamic organization of chromatin across mammalian cells & helps to improves the way cells are used in the discovery, development & manufacturing of recombinant proteins
• The biosimilar is used for CSU in patients with elevated IgE who do not respond to treatment with antihistamines in aged ≥12yrs.

Ref: Businesswire | Image: Businesswire